Tempsens Instruments (India) Ltd Q1 FY27 Results

Tempsens Instruments posted its first quarterly result as a listed company for Q1 FY27, with consolidated revenue of ₹118.7 Cr (+33.4% YoY, -11.0% QoQ) and consolidated PAT of ₹16.3 Cr (+15.6% YoY, -22.8% QoQ). The QoQ dip mirrors a sequentially stronger March 2026 quarter (revenue ₹133.3 Cr, PAT ₹21.1 Cr) rather than fresh deterioration. Reported consolidated profit growth trails revenue growth by roughly half, and the standalone (core, like-for-like) numbers tell a sharper version of the same story: standalone revenue grew 21.9% YoY to ₹101.9 Cr, but standalone PAT rose just 2.9% YoY to ₹12.9 Cr, as operating margin (PBT/revenue) compressed from 19.6% to 16.9%. Consolidated and standalone diverge materially in growth (33% vs 22% revenue, 16% vs 3% PAT) — the gap is driven by three subsidiaries (Tempsens GmbH, Tempsens Polska, and Tempsens Measurement and Control) added to the consolidated scope through FY26 and the JV equity pickup that has no standalone counterpart, so readers comparing the two bases should weight standalone as the truer read of the core business.

The margin compression sits on the cost lines: cost of materials consumed rose to 56.4% of consolidated revenue from 53.4% a year ago, and employee benefits expense rose to 17.2% of revenue from 15.8%, together eating roughly 270 basis points off standalone operating margin. No exceptional items or one-offs are disclosed, so this reads as genuine cost-push rather than an accounting artifact.

Consolidated scope expanded during FY26 with 3 new subsidiaries (Germany, Poland, Measurement & Control units) plus ₹0.68 Cr JV equity income — inflates consol growth versus standalone

EPS: consolidated basic ₹1.88 (vs ₹1.65 YoY) — standalone basic ₹1.60 (vs ₹1.56 YoY)

Against our pre-result preview — which flagged standalone revenue of ₹120–130 Cr, EBITDA margin of 24–25%, and PAT margin of 15–16% as the on-plan bar — the quarter missed on all three: standalone revenue landed at ₹101.9 Cr (below the low end), standalone EBITDA margin worked out to roughly 21.5%, and standalone PAT margin to 12.7%. There is no formal analyst consensus yet — a web check confirms platforms like Trendlyne still show no published estimates for the stock — consistent with our preview's read that coverage is thin post-listing; management has issued no formal guidance in this filing either. The one corporate milestone worth noting is the ₹650 Cr IPO (₹95 Cr fresh issue) that completed on 28 August 2026, after this quarter closed — this is the first result the company has drawn up under Listing Regulations, and the filing discloses nothing yet on capex plans or use of IPO proceeds, leaving that a genuine open item for Q2.

Tempsens Instruments (TEMPSENS) reports Q1 FY2027 results on September 16, 2026—its first full quarter as a public company. Listed on August 28 at ₹634 (111% above the ₹300 IPO price), the stock has since corrected to ₹571, signalling a repricing of the initial euphoria. The Street will be watching two things: (1) whether the company sustains its 27% revenue CAGR from FY24–FY26 (₹278 Cr → ₹455.86 Cr), and (2) whether EBITDA margins hold at or above the 24–25% levels seen in recent periods. At a PE of 64.28, there is little margin for disappointment.

A strong quarter would mean: (1) revenue growth >27% YoY and operating leverage intact; (2) EBITDA margin ≥24%; and (3) order-book commentary indicating sustained momentum. A weak quarter would signal: (1) revenue growth <20% YoY or seasonal softness; (2) margin compression below 22% (signalling input cost pressure or inefficiency); and (3) muted order traction or delayed project execution.

The company has not yet disclosed FY2027 guidance in its IPO filing or post-listing disclosures. For context, FY26 saw ₹455.86 Cr revenue and 15.59% PAT margin—solid metrics for a capital-intensive thermal and cable specialist. Q1 FY25 (if available) would provide seasonality calibration; absent that, assume Q1 as a typical 25% of FY26 annualized (i.e., ₹113–120 Cr). If the company can post >₹120 Cr with stable margins, it signals that the IPO window closure and public scrutiny have not disrupted operations.

Corporate event scan: The trading window was closed from August 29, 2026, until 48 hours post-results (i.e., until Sep 18). The board is scheduled to meet on September 16 to approve Q1 FY27 unaudited standalone and consolidated results. No material updates, promoter pledges, or regulatory flags have emerged since listing. The bulk/block activity above reflects HNI and MF repositioning; no insider-linked entities are evident. Routine.

Q1 delivers 33% revenue and 16% PAT growth with export momentum (78% growth, 34% of mix), supporting management's strategic expansion narrative. However, EBITDA margin compressed 330 bps YoY (22.4% vs 25.3%) due to 140 bps headcount investment and ESOP charges—near-term profitability pressure that management expects to absorb into revenue growth by year-end. Capacity projects (INR 500 Cr potential) are credible but execution-dependent; no quantified guidance on ramp timing or margin recovery targets. Hold pending clarity on capex execution and H2 margin trajectory.

Analysts pressed hard on margin recovery timing, new product contribution, and capex ramp visibility. Jenish Karia (Union AMC) questioned when full margin recovery occurs; management deferred to H2 FY27 partial recovery, H2 FY28 full recovery as new capacity absorbs headcount. Vedant S (MARS) asked for explicit capex run-rate by FY29; management gave blended growth guidance but no binding timeline. Overall tone: confident on strategy, defensive on numbers.

Score 7/10. Clear on business model, transparent on near-term headwinds (margin pressure, facility delays). Selective on quantified guidance (won't commit exact fuel cell ramp, order book size). Comfortable discussing strategy but cautious on timelines. Track record mixed. FY24–26 delivered 27% CAGR and 36% EBITDA growth (positive). Heater facility commissioned late Q1 (negative). Cable segment timing-dependent (neutral). OEM partnerships early-stage, unproven at scale.